Evidence-based · Educational only•
36+ Peptides indexed•
Free research library•
Free newsletter — subscribe below•
★ = FDA-approved medical indication•
Not medical advice — always consult a clinician•
Evidence-based · Educational only•
36+ Peptides indexed•
Free research library•
Free newsletter — subscribe below•
★ = FDA-approved medical indication•
Not medical advice — always consult a clinician•
Peptide Knowledge Center
All peptides

Octreotide

Also known as: Sandostatin
FDA-Approved

Octreotide is a long-acting somatostatin analog used to manage carcinoid syndrome, VIPomas, and acromegaly.

Buy Octreotide on American Peptides

Affiliate link — we may earn a commission at no extra cost to you.

Overview

Octreotide is a long-acting somatostatin analog used to manage carcinoid syndrome, VIPomas, and acromegaly.

FDA Approval Status

Approved by the FDA for at least one medical indication (see approved uses below).

Mechanism of Action

Somatostatin receptor agonism suppresses GH, insulin, glucagon, and various GI hormones.

Current Research

Established.
Research strength: Strong

Potential Medical Uses

  • Acromegaly
  • Carcinoid syndrome
  • VIPoma

Potential Benefits

  • Symptom control in NETs
  • Tumor stabilization in some patients

Known Side Effects

  • GI upset
  • Gallstones
  • Hyperglycemia

Contraindications

  • Hypersensitivity

Drug Interactions

  • Insulin
  • Cyclosporine

Administration Methods

  • Subcutaneous injection
  • LAR depot IM

Half-life

~1.5 hours (immediate release)

Reconstitution

LAR requires kit-based reconstitution.

Storage & Handling

Refrigerate.

References & Sources

Frequently Asked Questions

Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.